Cancer Biology Research federal obligations in FY2024

Cancer Biology Research × FY2024 is CFDA 93.396, not a trial-enrollment count, a cancer-incidence atlas, or a treatment-guideline vote

$5,637,300,324.70 is the obligation sum USAspending.gov attributes to Cancer Biology Research in FY2024 on the yearlyTrend series. It is not the government-wide FY2024 total and not an outlay. The FY cell is 84.5% of the program-wide $6,672,662,526.62 book in this extract. Campaign-finance filings do not fund these USAspending obligations. Do not invent contractors or award recipients; this packet lists none.

Readers sometimes treat a CFDA–year total as a budget Congress passed for a named activity. $5,637,300,324.70 is not that. It is the USAspending obligation rollup tagged to Cancer Biology Research and fiscal year 2024. Cite both sides. Unique recipients are unpublished.

Unpacking the Cancer Biology Research side

The catalog string is CANCER BIOLOGY RESEARCH. CFDA 93.396 is the program parent without a FY2024 filter. Program-wide obligations $6,672,662,526.62 and 3,004 parent awards describe that parent, not the year cell alone. Confusing this join with Cancer Cause and Prevention Research and other cancer catalog lines with different CFDA numbers would leave this overlay. Cancer Biology Research (CFDA 93.396) is not the same overlay as cause-and-prevention research on a different CFDA. Mixing those listings into the FY2024 cell would invent a combined cancer total the packet never computed. The packet publishes no disease-site split and no named institutions. Keep the biology listing and FY2024 on the same citation.

SpendingVault does not grade Cancer Biology Research on outcomes. $5,637,300,324.70 is an obligation sum, not a scorecard. Place-of-performance geography is unpublished here.

Unpacking fiscal year 2024

FY2024 federal spending is the year parent without a CFDA 93.396 filter. FY2024 figures can be incomplete for a current year. Awards that list another fiscal year sit outside this cell. Do not treat $6,672,662,526.62 as the FY2024 headline. Calendar-year statistics are not this time key.

2,394 award records versus 2,394 completed studies or 2,394 unique laboratories

2,394 year-cell awards are not 2,394 completed studies or 2,394 unique laboratories. Dividing $5,637,300,324.70 by 2,394 yields about $2,354,762.04, a quotient, not a typical invoice. Modifications can add rows. The parent count 3,004 is an all-year table. Mixing the year dollars with the parent count invents a per-award figure this packet does not publish.

Caveats on Cancer Biology Research obligations in FY2024

An obligation is a commitment. An outlay is a Treasury payment. $5,637,300,324.70 is the commitment figure. The join cannot support a named-lab roster, a principal-investigator directory, or a tumor-type split. Keep the obligation label. If a chart mixes Cancer Cause and Prevention Research and other cancer catalog lines with different CFDA numbers with CFDA 93.396 in FY2024, the chart has left this join.

Hubs: /programs/93.396/ (CFDA 93.396), /fiscal-years/2024/ (FY2024 federal spending), /programs/ (All programs), /ties/ (All spending ties). None convert this cell into a recipient list. Cite Cancer Biology Research, FY2024, CFDA 93.396, $5,637,300,324.70, 2,394 awards, USAspending.gov, obligations only. Keep Cancer Biology Research and FY2024 on the same line as $5,637,300,324.70. CFDA 93.396 remains the program key; fiscal year 2024 remains the time key. Obligations of $5,637,300,324.70 are not outlays and not a named-lab roster, a principal-investigator directory, or a tumor-type split. Original filings remain on USAspending.gov for this yearlyTrend cell. Campaign-finance tables do not fund these USAspending obligations. Unique recipients remain unpublished on this program-year join. All programs and All spending ties are larger indexes than this cell. A later USAspending ingest can restate $5,637,300,324.70 without changing CFDA 93.396 or FY2024. Do not invent contractors or award recipients for Cancer Biology Research. The 2,394 year-cell awards are still not 2,394 completed studies or 2,394 unique laboratories.

Questions

How much Cancer Biology Research spending is in FY2024?

USAspending.gov records $5,637,300,324.70 in Cancer Biology Research obligations for FY2024 (CFDA 93.396). That is a program × year join, not an outlay and not the government-wide FY2024 total. Original filings remain on USAspending.gov.

Do 2,394 awards mean 2,394 cancer studies finished in FY2024?

No. 2,394 is the year-cell award-record count, not 2,394 completed studies or 2,394 unique laboratories. A mean of about $2,354,762.04 is arithmetic on packet facts, not a typical payment. Unique recipients are unpublished. Original filings remain on USAspending.gov.

Is $5,637,300,324.70 cash already paid for Cancer Biology Research in FY2024?

No. $5,637,300,324.70 is an obligation aggregate for Cancer Biology Research in FY2024. Outlays, remaining balances, and cash already paid are unpublished on this packet. Keep the obligation label. USAspending.gov remains the source. Keep Cancer Biology Research and FY2024 together when citing $5,637,300,324.70.

Which pages parent Cancer Biology Research FY2024?

CFDA 93.396 is the program parent. FY2024 federal spending is the year parent. All programs lists other CFDA hubs. All spending ties lists other pairs. Prefer those tables after later ingests; this page quotes Cancer Biology Research × FY2024 at $5,637,300,324.70.